Article

Promising Cancer Drug Trials Highlight SPT Week in Review

Author(s):

Specialty Pharmacy Times Staff

Top articles of the week from Specialty Pharmacy Times.

[<a href="//storify.com/pharmacytimes/promising-cancer-drug-trials-highlight-spt-week-in" target="_blank">View the story "Promising Cancer Drug Trials Highlight SPT Week in Review" on Storify</a>]

Related Videos
World Standards Week 2024: US Pharmacopeia’s Achievements and Future Focus in Pharmacy Standards
October is American Pharmacists Month.
smiling indian male doctor or pharmacist in white coat with stethoscope and clipboard over drugstore background
Efficient healthcare supply chain management ensures timely delivery of medical supplies and medications
Pharmacy Benefit Manager Transparency | Image Credit: I Viewfinder - stock.adobe.com
Pharmacy Benefit Manager Regulation | Image Credit: Tyler Olson - stock.adobe.com
Naloxone concept represented by wooden letter tiles.
Hand holding a Narcan Evzio Naloxone nasal spray opioid drug overdose prevention medication
Related Content
Pharmacists Can Contribute to Management of Restless Legs Syndrome Augmentation
November 26th 2024

Pharmacists Can Contribute to Management of Restless Legs Syndrome Augmentation

Kamila Dymala, PharmD, RPh, MBA, BCMTM, PACS
Pharmacy Focus: World Psychedelics Day
June 14th 2024

Pharmacy Focus: World Psychedelics Day

Ashley Gallagher, Associate Editor
Sjogren Disease, FDA, Nipocalimab, Lupus, Rheumatoid Arthritis | Image Credit: © fizkes | stock.adobe.com
November 19th 2024

FDA Grants Breakthrough Therapy Designation for Nipocalimab to Treat Sjögren Disease

Ashley Gallagher, Associate Editor
Season 3 - Public Health Matters: A Look at Wearable Technology, AI-Assisted Innovations
January 25th 2024

Season 3 - Public Health Matters: A Look at Wearable Technology, AI-Assisted Innovations

Biosimilar, Ocrelizumab, Multiple Sclerosis | Image Credit: ralwel - stock.adobe.com
November 12th 2024

Proposed Biosimilar to Ocrelizumab Shows Comparability With Reference Product

Ashley Gallagher, Associate Editor
Diabetes, Cagrilintinide, Semagliutide | Image Credit: millaf - stock.adobe.com
November 11th 2024

An Overlook of Cagrilintinide and Semaglutide as it Progresses Through Phase 3 Trials

Vidhi Patel, PharmD Candidate